Navigation Links
UMMS researcher Victor Ambros, Ph.D., named co-recipient of 2012 Janssen Award for Biomedical Research

WORCESTER, MA Longtime collaborators Victor R. Ambros, PhD, of the University of Massachusetts Medical School (UMMS) and Gary B. Ruvkun, PhD, of Massachusetts General Hospital and Harvard Medical School, were awarded the 2012 Dr. Paul Janssen Award for Biomedical Research today by Johnson & Johnson for their co-discovery of microRNA, tiny molecules that are now understood to play a powerful role in gene expression and regulation. The award was announced during an event at the Biotechnology Industry Organization International Convention in Boston.

The award was created by Johnson & Johnson to honor the legacy of one of the most passionate, creative and productive scientists of the 20th century, Dr. Paul Janssen (1926-2003). The legacy of Dr. Paul as he was known in the scientific community continues to inspire the company's commitment to developing innovative solutions for unmet medical needs. Dr. Paul's work led to breakthroughs in several fields, including pain management, psychiatry, infectious disease and gastroenterology. Four of the drugs discovered by Dr. Paul and his team remain on the World Health Organization's list of essential medicines.

This is the second time in six years that a UMass Medical School scientist has been recognized by the Janssen Award selection committee. UMass Medical School professor Craig C. Mello won the inaugural Janssen Award in 2006.

"Victor is one of the great pioneers of microRNAi and an integral member of an exceptional community of RNA researchers here at UMass Medical School. Together, these faculty are advancing the world's understanding of fundamental biological mechanisms and furthering the field of biomedical sciences," said Chancellor Michael F. Collins, MD. "We are delighted to see Victor recognized with this remarkable award from his colleagues and fellow scientists."

"Victor's pioneering discovery of microRNA occurred at a time when the field was not mentally prepared to understand its full significance. We now know that microRNAs have key functions in a variety of human diseases, ranging from hyperlipidemia (high blood cholesterol) to cancer," said Terence R. Flotte, MD, executive deputy chancellor, provost, and dean of the School of Medicine.

Since the discovery of microRNAs in 1993, these regulatory molecules have been implicated in a wide range of both normal and pathological activities including embryonic development, blood-cell specialization, muscle function, heart disease and viral infections. Their discovery has opened new fields of research and has implications for the development of new therapeutic treatments and diagnostic tools.

Working independently, Dr. Ambros and Dr. Ruvkun led the groups that identified the first microRNA and the first microRNA target. Dr. Ambros' lab yielded the discovery of the first microRNA and Dr. Ruvkun's lab identified how that microRNA regulates its target messenger. Working together, they demonstrated that the microRNA inactivates its target through direct, base-pairing interactions. MicroRNAs have been linked to cancer and identified as regulators of numerous other developmental events in both plants and animals. As a result of this discovery, researchers are now exploring microRNAs for use in diagnosis and prognosis as well as potential therapies.

"We are honored to join the distinguished list of past awardees of the Dr. Paul Janssen Award for Biomedical Research," said Ambros, the Silverman Chair in Natural Sciences and professor in the Program in Molecular Medicine at UMass Medical School in Worcester, MA. "It is a testament to the wisdom of private and government patrons that fundamental research such as ours was supported over the years, and that it is paying off in new understanding of disease processesand possibly in cures for patients."

"Our research grew out of long-standing traditions in the field aiming to unearth molecular explanations for how biological systems work, with the hope that if an understanding was achieved, practical applications would likely emerge," said Ruvkun. "We have seen the small RNA field grow from our first papers to thousands of papers, many focused on particular diseases and treatments of diseases. The research has come full circle from fundamental biology to medicine just as we had hoped."

"The groundbreaking research of Dr. Ambros and Dr. Ruvkun has revolutionized the understanding of gene regulation, with significant implications for future developments in the medical field," said Paul Stoffels, MD, worldwide chairman of pharmaceuticals at Johnson & Johnson. "Perhaps equally important is the spirit of collaboration exemplified by these researchers exactly what Dr. Paul advocated in his own labs. Their success demonstrates that we can achieve so much more when we work together, rather than in silos."

The winners of the Dr. Paul Janssen Award for Biomedical Research are chosen by an independent committee of renowned scientists, including Nobel Laureates and Lasker Prize winners. The Award, which includes a $100,000 prize, will be presented to Drs. Ambros and Ruvkun in a ceremony followed by a scientific symposium at the New York Academy of Sciences in New York on September 7. For more information on the award or to request additional detail on the scientific symposium, please visit

Contact: Jim Fessenden
University of Massachusetts Medical School

Related medicine news :

1. Researchers reveal crucial immune fighter role of the STING protein
2. MDS researchers join forces to advance patient treatments and outcomes
3. Childhood obesity linked to math performance, MU researcher says
4. Stanford researchers discover the African cichlids noisy courtship ritual
5. Researchers determine pathway for origin of most common form of brain and spinal cord tumor
6. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
7. Children with asthma marginalized in movies, says Rutgers-Camden researcher
8. UCI researchers create mosquitoes incapable of transmitting malaria
9. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
10. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
11. VCU researchers identify changes in cholesterol metabolic pathways
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... The ... this summer, ushering in a new era of publicly accessible automated technology. Now, ... will continue to offer guests an up-close look at the shuttle at MOSI’s ...
(Date:11/30/2015)... ... 2015 , ... On Saturday, October 24th, 2015, at the Mill Race Park ... a 5K walk known as “Making Strides Against Breast Cancer”. Patients and staff members ... located in Battle Creek, joined in for this campaign that sought to raise donations ...
(Date:11/30/2015)... ... 30, 2015 , ... During the week of Thanksgiving, the ... for its research, education, support, and advocacy efforts. The campaign is held every ... Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds the ...
(Date:11/30/2015)... ... November 30, 2015 , ... According to Los Angeles bariatric surgeon Michael ... not necessarily caused by real hunger, but instead by a hormone called ghrelin ... that, while many patients are aware that weight loss surgery can help patients lose ...
(Date:11/30/2015)... ... 30, 2015 , ... A record crowd gathered at the Pennsylvania Biotech Center ... Baruch S. Blumberg Institute. , The institute, which is the research arm of the ... leaders for the conference, which focused on ways companies can work to reduce the ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
(Date:11/30/2015)... Nov. 30, 2015 NHS Supply Chain ... TrueBeam™ machines from Varian Medical Systems (NYSE: ... to replace older machines and institute modern radiotherapy ... public hospitals. The order, placed in September, also ... for Varian,s RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... N.J. , Nov. 30, 2015  Novartis will ... at the 57 th American Society of Hematology ... lymphomas and myelomas as well as supportive care, including ... addition to personalized cell therapies. The ASH Annual Meeting ... Florida . Novartis Oncology . "We ...
Breaking Medicine Technology: